Nat Commun: New cancer drug may promote tumor atrophy and reduce the side effects of therapy

2020 May 13 News /BioValleyBIOON / - a class of experimental anti-cancer drug called BET inhibitors or expected to help treat blood cancer, but it will induce serious toxic side effects, recently, a study published in the international Journal ofNatureCommunications, scientists from Yale University and other institutions have discovered a new type of inhibition by conducting animal studies agents that can potentially withstand a variety of cancers and solid tumors, compared to other formulations, its side effects are relatively smallSource: CC0PublicDomainresearchers QinYan said currently more small molecule drugs in a clinical trial of only aof tumor blood play a role, and the results of this study are expected to break this barrier; this new type of solid tumor inhibitor is expected to promote atrophy; researchers believe that this new inhibitor is expected to become the new anti-cancer major breakthrough in drug research, BET inhibitormore small molecule drugs currently being tested in clinical trialsthe only effective treatment of blood such as leukemia, multiple myeloma andlikecancer, but it can not effectively suppress most solid tumors, such as brain cancer, a breast and ovarian cancer a, but these drugs produce toxic side effects, including fatigue, nausea, poor appetite and platelet count low levelthis study, researchers studied animal models analyzed novel inhibitors NHWD-870 for ovarian cancer, small cell lung cancer, breast cancer, melanoma, lymphoma and a
therapeutic effect, and it found that, compared to the current BET inhibitor, NHWD-870 on efficiency against cancer cells is 3-50 times the formerNot as BET inhibitors as novel inhibitors NHWD-870 to show a strong ability to resist a solid tumor, which is part of proliferating macrophages (of TAMs) by inhibiting the proliferation of tumor-associated immune cells or leukocytes exert effect, the tumor cells can play of TAMs support system, thereby inhibiting the body's anti-tumor immunity, and to continue to promote tumor growth after treatmentNHWD-870 pair of TAMs effect is very obvious that a large number of leukocytes can be suppressed and diffusion will limit the growth of tumor, in addition, compared to other inhibitors, fewer side effects of the new inhibitorslast researcher Yan said the results of this study reveal not only the importance of targeting BRD4, but also reveals how its function to regulatetumor microenvironment,ongoing clinical trials related to human researchers, the relevant tests in the future they will be analyzed novel inhibitors NHWD-870 againstmelanoma and ovarian cancer effect(Biovalley Bioon.com) Original source:Yin, M., Guo, Y., Hu, R.etalPotentBRD4inhibitorsuppressescancercell-macrophageinteraction <br />NatCommun11,1833 (2020) .doi: 10.1038 / s41467-020-15290-0